<\/p>\n
If you or your child live with eczema, you know the drill: red, inflamed, itchy skin that flares without warning and can turn even a good night\u2019s sleep into a struggle. Dermatologists have long treated the condition a little differently depending on a patient\u2019s age, and new research offers some reassurance for families managing it at every stage of life.<\/p>\n
As reported by HCPLive<\/em>, a new analysis of tapinarof cream 1% (VTAMA), a once-daily, nonsteroidal treatment already FDA-approved for eczema, found that the cream performed consistently in toddlers and adults alike. Researchers pooled results from two major clinical trials and split participants into four age groups: 2 to 6, 7 to 11, 12 to 17 and adults 18 and older. About 80 percent of the study participants were children.<\/p>\n<\/div>\n Every single age group showed a real, measurable improvement over a placebo cream, with a meaningful share of patients reaching clear or almost clear skin. The trials weren\u2019t designed to pit the age groups against each other directly, but each one cleared the bar researchers set on its own. That consistency mattered, since eczema doesn’t behave the same way in a 2-year-old as it does in a middle-aged adult, and neither does a person\u2019s tolerance for a new medication.<\/p>\n \u201cEach one of these analyses showed they were statistically better than the vehicle in getting those high benchmarks of clear or almost clear or an EASI 75 response,\u201d said Detroit dermatologist Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health.<\/p>\n Stein Gold also pointed out why early results matter for a condition patients live with long-term. \u201cSo you can imagine how exhausting it is every single day to wake up and have red, inflamed, itchy skin,\u201d she said. \u201cIf we give a patient a new treatment and they start to see some improvement early on, especially within the first two weeks, that\u2019s actually quite exciting. If they see something early, they\u2019re more likely to stick with their treatment regimen and get the best results.\u201d<\/p>\n For families weighing eczema treatment options, the takeaway is a practical one: a therapy that performs consistently from early childhood through adulthood gives dermatologists one more tool they can reach for regardless of a patient\u2019s age. If you\u2019re managing flares at home, this is a good prompt to ask your derm whether an age-appropriate nonsteroidal option like tapinarof makes sense for you or your family.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":" If you or your child live with eczema, you know the dri […]<\/p>\n","protected":false},"author":1,"featured_media":2703,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"_links":{"self":[{"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/posts\/2702"}],"collection":[{"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/comments?post=2702"}],"version-history":[{"count":0,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/posts\/2702\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/media\/2703"}],"wp:attachment":[{"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/media?parent=2702"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/categories?post=2702"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/tags?post=2702"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What the New Data Shows<\/h2>\n
Why Age-by-Age Data Matters<\/h2>\n
Why Speed Matters for a Lifelong Condition<\/h2>\n
What This Means for Patients and Families<\/h2>\n